Key Highlights

  • Ardelyx shares fell approximately 17.04 percent in pre-market trading to $4.04 from Wednesday's close of $4.87, after dropping sharply after hours.
  • Second quarter revenue of $118 to $121 million missed the $121.6 million consensus estimate.
  • Adjusted EPS loss of $0.07 to $0.09 came in wider than the consensus estimate of a $0.05 loss.
  • Softer than anticipated IBSRELA and XPHOZAH sales momentum raised concerns about the near-term path toward profitability.

Wide Miss Sends Shares Sharply Lower

Ardelyx, Inc. (NASDAQ:ARDX) traded down approximately 17.04 percent in pre-market activity, near $4.04 versus Wednesday's close of $4.87, extending a decline that began immediately after the company's after-hours release. Revenue of $118 to $121 million fell short of the $121.6 million consensus, while the adjusted loss of $0.07 to $0.09 per share was wider than the $0.05 loss expected.

Softer Sales on Both Lead Products

The miss was driven by softer than anticipated sales momentum for both IBSRELA, the company's treatment for irritable bowel syndrome with constipation, and XPHOZAH, its therapy for hyperphosphatemia in dialysis patients. The shortfall renewed investor concerns about the company's timeline toward near-term profitability.

Analyst Price Targets Cut

The disappointing results prompted a wave of analyst price target cuts overnight, compounding pressure into Thursday's session. The scale of the decline reflects a broader reassessment of the growth trajectory investors had built into the stock following prior bullish management commentary.

Conclusion

Ardelyx's sharp decline reflects a rare dual miss on both revenue and earnings, compounded by softer commercial momentum across its two key products and a wave of analyst target cuts. The scale of the reaction suggests the market had priced in continued acceleration heading into the print.